nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—MAPK8—Parkinson's disease	0.408	0.577	CbGaD
Nilotinib—ABL1—Parkinson's disease	0.207	0.293	CbGaD
Nilotinib—CYP2D6—Parkinson's disease	0.0537	0.0758	CbGaD
Nilotinib—ABCB1—Parkinson's disease	0.0383	0.0542	CbGaD
Nilotinib—Imatinib—NQO2—Parkinson's disease	0.002	0.334	CrCbGaD
Nilotinib—Ponatinib—ABL1—Parkinson's disease	0.0017	0.285	CrCbGaD
Nilotinib—Imatinib—ABL1—Parkinson's disease	0.00105	0.176	CrCbGaD
Nilotinib—MAPK11—head—Parkinson's disease	0.000543	0.00489	CbGeAlD
Nilotinib—MAPK14—forebrain—Parkinson's disease	0.00054	0.00487	CbGeAlD
Nilotinib—CDC42BPB—head—Parkinson's disease	0.000538	0.00485	CbGeAlD
Nilotinib—EPHA8—central nervous system—Parkinson's disease	0.000533	0.00481	CbGeAlD
Nilotinib—EPHA8—cerebellum—Parkinson's disease	0.000521	0.0047	CbGeAlD
Nilotinib—MAPK11—nervous system—Parkinson's disease	0.000514	0.00464	CbGeAlD
Nilotinib—CDC42BPB—nervous system—Parkinson's disease	0.00051	0.0046	CbGeAlD
Nilotinib—EPHA3—head—Parkinson's disease	0.00051	0.0046	CbGeAlD
Nilotinib—PDGFRA—embryo—Parkinson's disease	0.000502	0.00452	CbGeAlD
Nilotinib—MAPK11—central nervous system—Parkinson's disease	0.000495	0.00447	CbGeAlD
Nilotinib—CDC42BPB—central nervous system—Parkinson's disease	0.000491	0.00443	CbGeAlD
Nilotinib—CA3—cardiovascular system—Parkinson's disease	0.000489	0.00441	CbGeAlD
Nilotinib—MAPK8—head—Parkinson's disease	0.000487	0.00439	CbGeAlD
Nilotinib—EPHA6—head—Parkinson's disease	0.000487	0.00439	CbGeAlD
Nilotinib—MAPK11—cerebellum—Parkinson's disease	0.000484	0.00437	CbGeAlD
Nilotinib—EPHA3—nervous system—Parkinson's disease	0.000484	0.00436	CbGeAlD
Nilotinib—CDC42BPB—cerebellum—Parkinson's disease	0.00048	0.00433	CbGeAlD
Nilotinib—EPHB6—forebrain—Parkinson's disease	0.000468	0.00422	CbGeAlD
Nilotinib—BRAF—midbrain—Parkinson's disease	0.000467	0.00421	CbGeAlD
Nilotinib—EPHA3—central nervous system—Parkinson's disease	0.000466	0.0042	CbGeAlD
Nilotinib—HCK—medulla oblongata—Parkinson's disease	0.000465	0.0042	CbGeAlD
Nilotinib—MAPK8—nervous system—Parkinson's disease	0.000461	0.00416	CbGeAlD
Nilotinib—EPHA6—nervous system—Parkinson's disease	0.000461	0.00416	CbGeAlD
Nilotinib—CA4—hindbrain—Parkinson's disease	0.000458	0.00413	CbGeAlD
Nilotinib—MAPK14—cardiovascular system—Parkinson's disease	0.000456	0.00412	CbGeAlD
Nilotinib—FGR—cardiovascular system—Parkinson's disease	0.000455	0.0041	CbGeAlD
Nilotinib—EPHB3—spinal cord—Parkinson's disease	0.000452	0.00407	CbGeAlD
Nilotinib—LYN—head—Parkinson's disease	0.000449	0.00405	CbGeAlD
Nilotinib—MAPK8—central nervous system—Parkinson's disease	0.000444	0.00401	CbGeAlD
Nilotinib—EPHA6—central nervous system—Parkinson's disease	0.000444	0.00401	CbGeAlD
Nilotinib—PDGFRA—forebrain—Parkinson's disease	0.000444	0.004	CbGeAlD
Nilotinib—CSF1R—embryo—Parkinson's disease	0.000442	0.00398	CbGeAlD
Nilotinib—Ponatinib—CYP2D6—Parkinson's disease	0.000441	0.0739	CrCbGaD
Nilotinib—EPHB2—brain—Parkinson's disease	0.000441	0.00398	CbGeAlD
Nilotinib—MAPK8—cerebellum—Parkinson's disease	0.000434	0.00392	CbGeAlD
Nilotinib—EPHB4—cardiovascular system—Parkinson's disease	0.000433	0.0039	CbGeAlD
Nilotinib—LYN—nervous system—Parkinson's disease	0.000426	0.00384	CbGeAlD
Nilotinib—HCK—midbrain—Parkinson's disease	0.000425	0.00384	CbGeAlD
Nilotinib—EPHA2—cardiovascular system—Parkinson's disease	0.000424	0.00383	CbGeAlD
Nilotinib—EPHA4—medulla oblongata—Parkinson's disease	0.000423	0.00382	CbGeAlD
Nilotinib—EPHA8—brain—Parkinson's disease	0.000423	0.00381	CbGeAlD
Nilotinib—TIE1—head—Parkinson's disease	0.000422	0.00381	CbGeAlD
Nilotinib—CA7—midbrain—Parkinson's disease	0.000416	0.00375	CbGeAlD
Nilotinib—HCK—spinal cord—Parkinson's disease	0.000415	0.00374	CbGeAlD
Nilotinib—MAP2K5—brainstem—Parkinson's disease	0.000415	0.00374	CbGeAlD
Nilotinib—TEK—cardiovascular system—Parkinson's disease	0.000414	0.00374	CbGeAlD
Nilotinib—LYN—central nervous system—Parkinson's disease	0.00041	0.0037	CbGeAlD
Nilotinib—CA12—forebrain—Parkinson's disease	0.00041	0.00369	CbGeAlD
Nilotinib—EPHB3—head—Parkinson's disease	0.000401	0.00362	CbGeAlD
Nilotinib—KIT—embryo—Parkinson's disease	0.000401	0.00362	CbGeAlD
Nilotinib—TIE1—nervous system—Parkinson's disease	0.0004	0.00361	CbGeAlD
Nilotinib—MAPK11—brain—Parkinson's disease	0.000393	0.00355	CbGeAlD
Nilotinib—PDGFRB—embryo—Parkinson's disease	0.000392	0.00353	CbGeAlD
Nilotinib—CSF1R—forebrain—Parkinson's disease	0.000391	0.00352	CbGeAlD
Nilotinib—CDC42BPB—brain—Parkinson's disease	0.00039	0.00352	CbGeAlD
Nilotinib—TIE1—central nervous system—Parkinson's disease	0.000385	0.00347	CbGeAlD
Nilotinib—EPHB3—nervous system—Parkinson's disease	0.000381	0.00343	CbGeAlD
Nilotinib—CA2—hindbrain—Parkinson's disease	0.00038	0.00343	CbGeAlD
Nilotinib—CA14—medulla oblongata—Parkinson's disease	0.000379	0.00342	CbGeAlD
Nilotinib—TIE1—cerebellum—Parkinson's disease	0.000376	0.0034	CbGeAlD
Nilotinib—PDGFRA—cardiovascular system—Parkinson's disease	0.000375	0.00338	CbGeAlD
Nilotinib—EPHB4—medulla oblongata—Parkinson's disease	0.00037	0.00333	CbGeAlD
Nilotinib—EPHA3—brain—Parkinson's disease	0.00037	0.00333	CbGeAlD
Nilotinib—HCK—head—Parkinson's disease	0.000369	0.00333	CbGeAlD
Nilotinib—KIT—brainstem—Parkinson's disease	0.000368	0.00331	CbGeAlD
Nilotinib—EPHB3—central nervous system—Parkinson's disease	0.000366	0.0033	CbGeAlD
Nilotinib—BRAF—cerebellum—Parkinson's disease	0.000361	0.00326	CbGeAlD
Nilotinib—EPHB3—cerebellum—Parkinson's disease	0.000358	0.00323	CbGeAlD
Nilotinib—TEK—medulla oblongata—Parkinson's disease	0.000354	0.00319	CbGeAlD
Nilotinib—MAPK8—brain—Parkinson's disease	0.000353	0.00318	CbGeAlD
Nilotinib—EPHA6—brain—Parkinson's disease	0.000353	0.00318	CbGeAlD
Nilotinib—HCK—nervous system—Parkinson's disease	0.00035	0.00315	CbGeAlD
Nilotinib—CA6—head—Parkinson's disease	0.00035	0.00315	CbGeAlD
Nilotinib—ABL1—embryo—Parkinson's disease	0.000349	0.00315	CbGeAlD
Nilotinib—MAPK14—spinal cord—Parkinson's disease	0.000348	0.00314	CbGeAlD
Nilotinib—CA14—midbrain—Parkinson's disease	0.000347	0.00313	CbGeAlD
Nilotinib—MAP2K5—cardiovascular system—Parkinson's disease	0.000338	0.00305	CbGeAlD
Nilotinib—CA14—spinal cord—Parkinson's disease	0.000338	0.00305	CbGeAlD
Nilotinib—EPHB6—medulla oblongata—Parkinson's disease	0.000338	0.00305	CbGeAlD
Nilotinib—EPHB4—midbrain—Parkinson's disease	0.000338	0.00305	CbGeAlD
Nilotinib—HCK—central nervous system—Parkinson's disease	0.000337	0.00304	CbGeAlD
Nilotinib—EPHA4—head—Parkinson's disease	0.000335	0.00302	CbGeAlD
Nilotinib—CA3—head—Parkinson's disease	0.000331	0.00299	CbGeAlD
Nilotinib—CSF1R—cardiovascular system—Parkinson's disease	0.00033	0.00298	CbGeAlD
Nilotinib—EPHB4—spinal cord—Parkinson's disease	0.00033	0.00297	CbGeAlD
Nilotinib—ABL2—cerebellum—Parkinson's disease	0.000327	0.00295	CbGeAlD
Nilotinib—LYN—brain—Parkinson's disease	0.000325	0.00294	CbGeAlD
Nilotinib—CA1—forebrain—Parkinson's disease	0.000324	0.00293	CbGeAlD
Nilotinib—TEK—midbrain—Parkinson's disease	0.000323	0.00292	CbGeAlD
Nilotinib—CA7—cerebellum—Parkinson's disease	0.000322	0.0029	CbGeAlD
Nilotinib—MAP4K1—brain—Parkinson's disease	0.000321	0.00289	CbGeAlD
Nilotinib—ABL1—brainstem—Parkinson's disease	0.00032	0.00289	CbGeAlD
Nilotinib—EPHA4—nervous system—Parkinson's disease	0.000318	0.00287	CbGeAlD
Nilotinib—TEK—spinal cord—Parkinson's disease	0.000316	0.00285	CbGeAlD
Nilotinib—Ponatinib—ABCB1—Parkinson's disease	0.000315	0.0528	CrCbGaD
Nilotinib—CA3—nervous system—Parkinson's disease	0.000314	0.00283	CbGeAlD
Nilotinib—MAPK14—head—Parkinson's disease	0.000309	0.00279	CbGeAlD
Nilotinib—EPHB6—midbrain—Parkinson's disease	0.000309	0.00279	CbGeAlD
Nilotinib—FGR—head—Parkinson's disease	0.000308	0.00278	CbGeAlD
Nilotinib—EPHA4—central nervous system—Parkinson's disease	0.000306	0.00276	CbGeAlD
Nilotinib—TIE1—brain—Parkinson's disease	0.000306	0.00276	CbGeAlD
Nilotinib—CA3—central nervous system—Parkinson's disease	0.000302	0.00273	CbGeAlD
Nilotinib—EPHB6—spinal cord—Parkinson's disease	0.000302	0.00272	CbGeAlD
Nilotinib—KIT—cardiovascular system—Parkinson's disease	0.0003	0.00271	CbGeAlD
Nilotinib—EPHA4—cerebellum—Parkinson's disease	0.000299	0.0027	CbGeAlD
Nilotinib—BRAF—brain—Parkinson's disease	0.000293	0.00264	CbGeAlD
Nilotinib—MAPK14—nervous system—Parkinson's disease	0.000293	0.00264	CbGeAlD
Nilotinib—PDGFRB—cardiovascular system—Parkinson's disease	0.000293	0.00264	CbGeAlD
Nilotinib—FGR—nervous system—Parkinson's disease	0.000292	0.00263	CbGeAlD
Nilotinib—EPHB3—brain—Parkinson's disease	0.000291	0.00262	CbGeAlD
Nilotinib—MAP2K5—medulla oblongata—Parkinson's disease	0.000289	0.00261	CbGeAlD
Nilotinib—EPHA2—head—Parkinson's disease	0.000287	0.00259	CbGeAlD
Nilotinib—PDGFRA—spinal cord—Parkinson's disease	0.000286	0.00258	CbGeAlD
Nilotinib—CA9—cerebellum—Parkinson's disease	0.000283	0.00255	CbGeAlD
Nilotinib—CSF1R—medulla oblongata—Parkinson's disease	0.000282	0.00255	CbGeAlD
Nilotinib—MAPK14—central nervous system—Parkinson's disease	0.000282	0.00254	CbGeAlD
Nilotinib—FGR—central nervous system—Parkinson's disease	0.000281	0.00253	CbGeAlD
Nilotinib—TEK—head—Parkinson's disease	0.00028	0.00253	CbGeAlD
Nilotinib—MAPK14—cerebellum—Parkinson's disease	0.000276	0.00249	CbGeAlD
Nilotinib—CA1—cardiovascular system—Parkinson's disease	0.000274	0.00247	CbGeAlD
Nilotinib—EPHA2—nervous system—Parkinson's disease	0.000273	0.00246	CbGeAlD
Nilotinib—Imatinib—CYP2D6—Parkinson's disease	0.000272	0.0455	CrCbGaD
Nilotinib—CA14—cerebellum—Parkinson's disease	0.000268	0.00242	CbGeAlD
Nilotinib—EPHB6—head—Parkinson's disease	0.000268	0.00242	CbGeAlD
Nilotinib—HCK—brain—Parkinson's disease	0.000267	0.00241	CbGeAlD
Nilotinib—TEK—nervous system—Parkinson's disease	0.000266	0.0024	CbGeAlD
Nilotinib—ABL2—brain—Parkinson's disease	0.000266	0.0024	CbGeAlD
Nilotinib—MAP2K5—midbrain—Parkinson's disease	0.000264	0.00238	CbGeAlD
Nilotinib—CA4—brainstem—Parkinson's disease	0.000263	0.00237	CbGeAlD
Nilotinib—EPHA2—central nervous system—Parkinson's disease	0.000262	0.00237	CbGeAlD
Nilotinib—CA7—brain—Parkinson's disease	0.000262	0.00236	CbGeAlD
Nilotinib—EPHB4—cerebellum—Parkinson's disease	0.000261	0.00236	CbGeAlD
Nilotinib—ABL1—cardiovascular system—Parkinson's disease	0.000261	0.00235	CbGeAlD
Nilotinib—CSF1R—midbrain—Parkinson's disease	0.000258	0.00233	CbGeAlD
Nilotinib—MAP2K5—spinal cord—Parkinson's disease	0.000258	0.00233	CbGeAlD
Nilotinib—KIT—medulla oblongata—Parkinson's disease	0.000256	0.00231	CbGeAlD
Nilotinib—TEK—central nervous system—Parkinson's disease	0.000256	0.00231	CbGeAlD
Nilotinib—EPHB6—nervous system—Parkinson's disease	0.000254	0.00229	CbGeAlD
Nilotinib—PDGFRA—head—Parkinson's disease	0.000254	0.00229	CbGeAlD
Nilotinib—CA4—forebrain—Parkinson's disease	0.000254	0.00229	CbGeAlD
Nilotinib—CSF1R—spinal cord—Parkinson's disease	0.000252	0.00227	CbGeAlD
Nilotinib—PDGFRB—medulla oblongata—Parkinson's disease	0.00025	0.00226	CbGeAlD
Nilotinib—TEK—cerebellum—Parkinson's disease	0.00025	0.00226	CbGeAlD
Nilotinib—EPHB6—central nervous system—Parkinson's disease	0.000245	0.00221	CbGeAlD
Nilotinib—EPHA4—brain—Parkinson's disease	0.000243	0.00219	CbGeAlD
Nilotinib—CYP2D6—hindbrain—Parkinson's disease	0.000241	0.00218	CbGeAlD
Nilotinib—PDGFRA—nervous system—Parkinson's disease	0.000241	0.00217	CbGeAlD
Nilotinib—CA3—brain—Parkinson's disease	0.00024	0.00216	CbGeAlD
Nilotinib—EPHB6—cerebellum—Parkinson's disease	0.000239	0.00216	CbGeAlD
Nilotinib—CA2—embryo—Parkinson's disease	0.000238	0.00214	CbGeAlD
Nilotinib—CA12—head—Parkinson's disease	0.000234	0.00211	CbGeAlD
Nilotinib—KIT—midbrain—Parkinson's disease	0.000234	0.00211	CbGeAlD
Nilotinib—PDGFRA—central nervous system—Parkinson's disease	0.000232	0.00209	CbGeAlD
Nilotinib—MAP2K5—head—Parkinson's disease	0.000229	0.00207	CbGeAlD
Nilotinib—PDGFRB—midbrain—Parkinson's disease	0.000229	0.00206	CbGeAlD
Nilotinib—KIT—spinal cord—Parkinson's disease	0.000229	0.00206	CbGeAlD
Nilotinib—PDGFRA—cerebellum—Parkinson's disease	0.000227	0.00204	CbGeAlD
Nilotinib—MAPK14—brain—Parkinson's disease	0.000224	0.00202	CbGeAlD
Nilotinib—CSF1R—head—Parkinson's disease	0.000224	0.00202	CbGeAlD
Nilotinib—PDGFRB—spinal cord—Parkinson's disease	0.000223	0.00201	CbGeAlD
Nilotinib—ABL1—medulla oblongata—Parkinson's disease	0.000223	0.00201	CbGeAlD
Nilotinib—FGR—brain—Parkinson's disease	0.000223	0.00201	CbGeAlD
Nilotinib—CA12—nervous system—Parkinson's disease	0.000222	0.00201	CbGeAlD
Nilotinib—CA14—brain—Parkinson's disease	0.000218	0.00197	CbGeAlD
Nilotinib—CA2—brainstem—Parkinson's disease	0.000218	0.00196	CbGeAlD
Nilotinib—MAP2K5—nervous system—Parkinson's disease	0.000217	0.00196	CbGeAlD
Nilotinib—CA4—cardiovascular system—Parkinson's disease	0.000214	0.00193	CbGeAlD
Nilotinib—CA12—central nervous system—Parkinson's disease	0.000214	0.00193	CbGeAlD
Nilotinib—EPHB4—brain—Parkinson's disease	0.000212	0.00192	CbGeAlD
Nilotinib—CSF1R—nervous system—Parkinson's disease	0.000212	0.00191	CbGeAlD
Nilotinib—CA2—forebrain—Parkinson's disease	0.00021	0.0019	CbGeAlD
Nilotinib—MAP2K5—central nervous system—Parkinson's disease	0.000209	0.00189	CbGeAlD
Nilotinib—CA1—spinal cord—Parkinson's disease	0.000209	0.00189	CbGeAlD
Nilotinib—EPHA2—brain—Parkinson's disease	0.000208	0.00188	CbGeAlD
Nilotinib—MAP2K5—cerebellum—Parkinson's disease	0.000204	0.00184	CbGeAlD
Nilotinib—CSF1R—central nervous system—Parkinson's disease	0.000204	0.00184	CbGeAlD
Nilotinib—ABL1—midbrain—Parkinson's disease	0.000204	0.00184	CbGeAlD
Nilotinib—TEK—brain—Parkinson's disease	0.000203	0.00183	CbGeAlD
Nilotinib—KIT—head—Parkinson's disease	0.000203	0.00183	CbGeAlD
Nilotinib—CSF1R—cerebellum—Parkinson's disease	0.0002	0.0018	CbGeAlD
Nilotinib—ABL1—spinal cord—Parkinson's disease	0.000199	0.00179	CbGeAlD
Nilotinib—PDGFRB—head—Parkinson's disease	0.000198	0.00179	CbGeAlD
Nilotinib—EPHB6—brain—Parkinson's disease	0.000194	0.00175	CbGeAlD
Nilotinib—Imatinib—ABCB1—Parkinson's disease	0.000194	0.0325	CrCbGaD
Nilotinib—KIT—nervous system—Parkinson's disease	0.000193	0.00174	CbGeAlD
Nilotinib—PDGFRB—nervous system—Parkinson's disease	0.000188	0.0017	CbGeAlD
Nilotinib—CA1—head—Parkinson's disease	0.000186	0.00168	CbGeAlD
Nilotinib—KIT—central nervous system—Parkinson's disease	0.000185	0.00167	CbGeAlD
Nilotinib—PDGFRA—brain—Parkinson's disease	0.000184	0.00166	CbGeAlD
Nilotinib—CA4—medulla oblongata—Parkinson's disease	0.000183	0.00165	CbGeAlD
Nilotinib—KIT—cerebellum—Parkinson's disease	0.000181	0.00163	CbGeAlD
Nilotinib—PDGFRB—central nervous system—Parkinson's disease	0.000181	0.00163	CbGeAlD
Nilotinib—CA2—cardiovascular system—Parkinson's disease	0.000178	0.0016	CbGeAlD
Nilotinib—PDGFRB—cerebellum—Parkinson's disease	0.000177	0.0016	CbGeAlD
Nilotinib—ABL1—head—Parkinson's disease	0.000177	0.00159	CbGeAlD
Nilotinib—CA1—nervous system—Parkinson's disease	0.000176	0.00159	CbGeAlD
Nilotinib—CA12—brain—Parkinson's disease	0.00017	0.00153	CbGeAlD
Nilotinib—CA1—central nervous system—Parkinson's disease	0.00017	0.00153	CbGeAlD
Nilotinib—ABL1—nervous system—Parkinson's disease	0.000168	0.00151	CbGeAlD
Nilotinib—CA4—midbrain—Parkinson's disease	0.000167	0.00151	CbGeAlD
Nilotinib—MAP2K5—brain—Parkinson's disease	0.000166	0.0015	CbGeAlD
Nilotinib—CA4—spinal cord—Parkinson's disease	0.000163	0.00147	CbGeAlD
Nilotinib—CSF1R—brain—Parkinson's disease	0.000162	0.00146	CbGeAlD
Nilotinib—ABL1—central nervous system—Parkinson's disease	0.000161	0.00146	CbGeAlD
Nilotinib—ABL1—cerebellum—Parkinson's disease	0.000158	0.00142	CbGeAlD
Nilotinib—CA2—medulla oblongata—Parkinson's disease	0.000152	0.00137	CbGeAlD
Nilotinib—CYP2B6—cardiovascular system—Parkinson's disease	0.000152	0.00137	CbGeAlD
Nilotinib—CYP2C9—cardiovascular system—Parkinson's disease	0.00015	0.00136	CbGeAlD
Nilotinib—KIT—brain—Parkinson's disease	0.000147	0.00133	CbGeAlD
Nilotinib—CA4—head—Parkinson's disease	0.000145	0.00131	CbGeAlD
Nilotinib—PDGFRB—brain—Parkinson's disease	0.000144	0.0013	CbGeAlD
Nilotinib—ABCG2—medulla oblongata—Parkinson's disease	0.000141	0.00127	CbGeAlD
Nilotinib—CA2—midbrain—Parkinson's disease	0.000139	0.00125	CbGeAlD
Nilotinib—CYP2D6—brainstem—Parkinson's disease	0.000138	0.00125	CbGeAlD
Nilotinib—CA4—nervous system—Parkinson's disease	0.000138	0.00124	CbGeAlD
Nilotinib—CA2—spinal cord—Parkinson's disease	0.000135	0.00122	CbGeAlD
Nilotinib—CA1—brain—Parkinson's disease	0.000135	0.00121	CbGeAlD
Nilotinib—CYP2D6—forebrain—Parkinson's disease	0.000133	0.0012	CbGeAlD
Nilotinib—CA4—central nervous system—Parkinson's disease	0.000133	0.0012	CbGeAlD
Nilotinib—CA4—cerebellum—Parkinson's disease	0.00013	0.00117	CbGeAlD
Nilotinib—ABCG2—midbrain—Parkinson's disease	0.000129	0.00116	CbGeAlD
Nilotinib—ABL1—brain—Parkinson's disease	0.000128	0.00116	CbGeAlD
Nilotinib—ABCG2—spinal cord—Parkinson's disease	0.000125	0.00113	CbGeAlD
Nilotinib—CA2—head—Parkinson's disease	0.00012	0.00109	CbGeAlD
Nilotinib—CA2—nervous system—Parkinson's disease	0.000114	0.00103	CbGeAlD
Nilotinib—CA2—central nervous system—Parkinson's disease	0.00011	0.000991	CbGeAlD
Nilotinib—ABCB1—embryo—Parkinson's disease	0.000109	0.000979	CbGeAlD
Nilotinib—CA2—cerebellum—Parkinson's disease	0.000107	0.000969	CbGeAlD
Nilotinib—CA4—brain—Parkinson's disease	0.000105	0.000949	CbGeAlD
Nilotinib—CYP2B6—head—Parkinson's disease	0.000103	0.000928	CbGeAlD
Nilotinib—ABCG2—cerebellum—Parkinson's disease	9.95e-05	0.000897	CbGeAlD
Nilotinib—CYP2B6—nervous system—Parkinson's disease	9.75e-05	0.00088	CbGeAlD
Nilotinib—ABCB1—forebrain—Parkinson's disease	9.6e-05	0.000866	CbGeAlD
Nilotinib—CYP2B6—central nervous system—Parkinson's disease	9.39e-05	0.000847	CbGeAlD
Nilotinib—CA2—brain—Parkinson's disease	8.72e-05	0.000787	CbGeAlD
Nilotinib—CYP2C8—brain—Parkinson's disease	8.31e-05	0.00075	CbGeAlD
Nilotinib—ABCB1—cardiovascular system—Parkinson's disease	8.12e-05	0.000732	CbGeAlD
Nilotinib—ABCG2—brain—Parkinson's disease	8.08e-05	0.000729	CbGeAlD
Nilotinib—CYP2D6—head—Parkinson's disease	7.64e-05	0.000689	CbGeAlD
Nilotinib—CYP2B6—brain—Parkinson's disease	7.45e-05	0.000672	CbGeAlD
Nilotinib—CYP3A4—nervous system—Parkinson's disease	7.36e-05	0.000664	CbGeAlD
Nilotinib—CYP2D6—nervous system—Parkinson's disease	7.25e-05	0.000654	CbGeAlD
Nilotinib—CYP3A4—central nervous system—Parkinson's disease	7.09e-05	0.000639	CbGeAlD
Nilotinib—CYP2D6—central nervous system—Parkinson's disease	6.98e-05	0.000629	CbGeAlD
Nilotinib—ABCB1—medulla oblongata—Parkinson's disease	6.94e-05	0.000626	CbGeAlD
Nilotinib—CYP2D6—cerebellum—Parkinson's disease	6.82e-05	0.000615	CbGeAlD
Nilotinib—ABCB1—midbrain—Parkinson's disease	6.34e-05	0.000572	CbGeAlD
Nilotinib—ABCB1—spinal cord—Parkinson's disease	6.19e-05	0.000558	CbGeAlD
Nilotinib—CYP2D6—brain—Parkinson's disease	5.54e-05	0.0005	CbGeAlD
Nilotinib—ABCB1—head—Parkinson's disease	5.5e-05	0.000496	CbGeAlD
Nilotinib—ABCB1—nervous system—Parkinson's disease	5.21e-05	0.00047	CbGeAlD
Nilotinib—ABCB1—central nervous system—Parkinson's disease	5.02e-05	0.000453	CbGeAlD
Nilotinib—ABCB1—cerebellum—Parkinson's disease	4.91e-05	0.000442	CbGeAlD
Nilotinib—ABCB1—brain—Parkinson's disease	3.98e-05	0.000359	CbGeAlD
Nilotinib—CYP2C9—Metabolism—DDC—Parkinson's disease	4.37e-06	2.49e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—APOE—Parkinson's disease	4.32e-06	2.46e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—Parkinson's disease	4.31e-06	2.45e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—TNF—Parkinson's disease	4.29e-06	2.44e-05	CbGpPWpGaD
Nilotinib—MAPK11—Innate Immune System—IL6—Parkinson's disease	4.28e-06	2.44e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—APOE—Parkinson's disease	4.28e-06	2.44e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IGF2—Parkinson's disease	4.28e-06	2.44e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—IL1B—Parkinson's disease	4.26e-06	2.43e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—GPX1—Parkinson's disease	4.24e-06	2.41e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—ADRBK1—Parkinson's disease	4.23e-06	2.41e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—HTR2A—Parkinson's disease	4.19e-06	2.39e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IGF2—Parkinson's disease	4.19e-06	2.38e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—NGF—Parkinson's disease	4.17e-06	2.37e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GSTA4—Parkinson's disease	4.17e-06	2.37e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Parkinson's disease	4.16e-06	2.37e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—MAPK8—Parkinson's disease	4.14e-06	2.36e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IGF1R—Parkinson's disease	4.14e-06	2.36e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GSTA4—Parkinson's disease	4.13e-06	2.35e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—COMT—Parkinson's disease	4.11e-06	2.34e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—DRD2—Parkinson's disease	4.1e-06	2.33e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—HTR7—Parkinson's disease	4.1e-06	2.33e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—MTHFR—Parkinson's disease	4.09e-06	2.33e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—GSTP1—Parkinson's disease	4.09e-06	2.33e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—EDN1—Parkinson's disease	4.09e-06	2.33e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—Parkinson's disease	4.08e-06	2.32e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—MAOA—Parkinson's disease	4.08e-06	2.32e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—INS—Parkinson's disease	4.05e-06	2.31e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IGF1R—Parkinson's disease	4.05e-06	2.31e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—HMOX1—Parkinson's disease	4.03e-06	2.3e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—EDN1—Parkinson's disease	4e-06	2.28e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PLA2G6—Parkinson's disease	3.98e-06	2.27e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—CYP2D6—Parkinson's disease	3.97e-06	2.26e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IGF2—Parkinson's disease	3.97e-06	2.26e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—HTR2A—Parkinson's disease	3.97e-06	2.26e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—MAOB—Parkinson's disease	3.94e-06	2.24e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GBA—Parkinson's disease	3.93e-06	2.24e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—FBP1—Parkinson's disease	3.93e-06	2.24e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—DBH—Parkinson's disease	3.93e-06	2.24e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—MTHFR—Parkinson's disease	3.91e-06	2.23e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—MAPK8—Parkinson's disease	3.91e-06	2.23e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—CTGF—Parkinson's disease	3.9e-06	2.22e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—APOE—Parkinson's disease	3.9e-06	2.22e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—ABCB1—Parkinson's disease	3.87e-06	2.2e-05	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—IL6—Parkinson's disease	3.86e-06	2.2e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—IL1B—Parkinson's disease	3.84e-06	2.19e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IGF1R—Parkinson's disease	3.84e-06	2.19e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—APOE—Parkinson's disease	3.81e-06	2.17e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—EDN1—Parkinson's disease	3.79e-06	2.16e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—GSTM1—Parkinson's disease	3.76e-06	2.14e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—NGF—Parkinson's disease	3.75e-06	2.14e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PLA2G6—Parkinson's disease	3.75e-06	2.14e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PLA2G6—Parkinson's disease	3.72e-06	2.12e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—MAOB—Parkinson's disease	3.71e-06	2.12e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—INS—Parkinson's disease	3.69e-06	2.1e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—APOE—Parkinson's disease	3.69e-06	2.1e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—MAOB—Parkinson's disease	3.68e-06	2.1e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NGF—Parkinson's disease	3.68e-06	2.09e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—INS—Parkinson's disease	3.66e-06	2.08e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—IL6—Parkinson's disease	3.66e-06	2.08e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—IL6—Parkinson's disease	3.65e-06	2.08e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—APOE—Parkinson's disease	3.64e-06	2.07e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL1B—Parkinson's disease	3.64e-06	2.07e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—IL6—Parkinson's disease	3.63e-06	2.07e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—CYP2E1—Parkinson's disease	3.63e-06	2.07e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—GPX1—Parkinson's disease	3.6e-06	2.05e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—NQO1—Parkinson's disease	3.59e-06	2.05e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—HTR2A—Parkinson's disease	3.57e-06	2.04e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—TH—Parkinson's disease	3.54e-06	2.02e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—MAPK8—Parkinson's disease	3.52e-06	2.01e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—APOE—Parkinson's disease	3.5e-06	2e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—HTR2A—Parkinson's disease	3.5e-06	1.99e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NGF—Parkinson's disease	3.49e-06	1.98e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—IL6—Parkinson's disease	3.46e-06	1.97e-05	CbGpPWpGaD
Nilotinib—HCK—Immune System—IL6—Parkinson's disease	3.46e-06	1.97e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—CASP3—Parkinson's disease	3.45e-06	1.96e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IGF2—Parkinson's disease	3.43e-06	1.95e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—CYCS—Parkinson's disease	3.4e-06	1.94e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CYP2D6—Parkinson's disease	3.36e-06	1.91e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—MAPK8—Parkinson's disease	3.34e-06	1.9e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—INS—Parkinson's disease	3.33e-06	1.9e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—APOE—Parkinson's disease	3.32e-06	1.89e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—MTHFR—Parkinson's disease	3.32e-06	1.89e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IGF1R—Parkinson's disease	3.32e-06	1.89e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—HTR2A—Parkinson's disease	3.32e-06	1.89e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CTGF—Parkinson's disease	3.3e-06	1.88e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—IL6—Parkinson's disease	3.29e-06	1.88e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CASP3—Parkinson's disease	3.28e-06	1.87e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—EDN1—Parkinson's disease	3.28e-06	1.87e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL1B—Parkinson's disease	3.28e-06	1.87e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—APOE—Parkinson's disease	3.25e-06	1.85e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—INS—Parkinson's disease	3.25e-06	1.85e-05	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—IL6—Parkinson's disease	3.23e-06	1.84e-05	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—IL6—Parkinson's disease	3.21e-06	1.83e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL1B—Parkinson's disease	3.21e-06	1.83e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL1B—Parkinson's disease	3.19e-06	1.82e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—IL6—Parkinson's disease	3.19e-06	1.82e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—INS—Parkinson's disease	3.15e-06	1.79e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—IL6—Parkinson's disease	3.13e-06	1.78e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—IL6—Parkinson's disease	3.13e-06	1.78e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—IL6—Parkinson's disease	3.12e-06	1.78e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—INS—Parkinson's disease	3.11e-06	1.77e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—APOE—Parkinson's disease	3.09e-06	1.76e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—APOE—Parkinson's disease	3.08e-06	1.76e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CYP2E1—Parkinson's disease	3.08e-06	1.75e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—IL6—Parkinson's disease	3.06e-06	1.74e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL1B—Parkinson's disease	3.04e-06	1.73e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—NQO1—Parkinson's disease	3.04e-06	1.73e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—MAPK8—Parkinson's disease	3.01e-06	1.72e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NGF—Parkinson's disease	3.01e-06	1.72e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—COMT—Parkinson's disease	3.01e-06	1.71e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—MAPK8—Parkinson's disease	3e-06	1.71e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—TH—Parkinson's disease	3e-06	1.71e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—GSTP1—Parkinson's disease	3e-06	1.71e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—MAOA—Parkinson's disease	2.99e-06	1.7e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—HMOX1—Parkinson's disease	2.95e-06	1.68e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—MAPK8—Parkinson's disease	2.94e-06	1.68e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CYP2D6—Parkinson's disease	2.93e-06	1.67e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—MAPK8—Parkinson's disease	2.93e-06	1.67e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—DDC—Parkinson's disease	2.88e-06	1.64e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CYCS—Parkinson's disease	2.88e-06	1.64e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CTGF—Parkinson's disease	2.88e-06	1.64e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—HTR2A—Parkinson's disease	2.87e-06	1.63e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—INS—Parkinson's disease	2.84e-06	1.62e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—ABCB1—Parkinson's disease	2.84e-06	1.61e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—MAPK8—Parkinson's disease	2.79e-06	1.59e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—INS—Parkinson's disease	2.78e-06	1.58e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—GSTM1—Parkinson's disease	2.75e-06	1.57e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CASP3—Parkinson's disease	2.75e-06	1.57e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CYP2D6—Parkinson's disease	2.74e-06	1.56e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GSTA4—Parkinson's disease	2.72e-06	1.55e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CASP3—Parkinson's disease	2.72e-06	1.55e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CTGF—Parkinson's disease	2.71e-06	1.54e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CTGF—Parkinson's disease	2.69e-06	1.53e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CYP2E1—Parkinson's disease	2.68e-06	1.53e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—APOE—Parkinson's disease	2.67e-06	1.52e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—NQO1—Parkinson's disease	2.65e-06	1.51e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—IL6—Parkinson's disease	2.64e-06	1.51e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—INS—Parkinson's disease	2.64e-06	1.5e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—GPX1—Parkinson's disease	2.64e-06	1.5e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—INS—Parkinson's disease	2.63e-06	1.5e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL1B—Parkinson's disease	2.63e-06	1.5e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—TH—Parkinson's disease	2.61e-06	1.49e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—COMT—Parkinson's disease	2.55e-06	1.45e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GSTP1—Parkinson's disease	2.54e-06	1.44e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—MAOA—Parkinson's disease	2.53e-06	1.44e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MAPK8—Parkinson's disease	2.53e-06	1.44e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CYP2E1—Parkinson's disease	2.52e-06	1.44e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CYCS—Parkinson's disease	2.51e-06	1.43e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CYP2E1—Parkinson's disease	2.5e-06	1.43e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MAPK8—Parkinson's disease	2.5e-06	1.43e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—HMOX1—Parkinson's disease	2.5e-06	1.42e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—NQO1—Parkinson's disease	2.5e-06	1.42e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—IL6—Parkinson's disease	2.5e-06	1.42e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CASP3—Parkinson's disease	2.48e-06	1.41e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—NQO1—Parkinson's disease	2.47e-06	1.41e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—TH—Parkinson's disease	2.46e-06	1.4e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PLA2G6—Parkinson's disease	2.45e-06	1.4e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—TH—Parkinson's disease	2.44e-06	1.39e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—MTHFR—Parkinson's disease	2.43e-06	1.39e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—MAOB—Parkinson's disease	2.43e-06	1.38e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—MAPK8—Parkinson's disease	2.41e-06	1.37e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ABCB1—Parkinson's disease	2.4e-06	1.37e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CYCS—Parkinson's disease	2.36e-06	1.35e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CASP3—Parkinson's disease	2.35e-06	1.34e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CYCS—Parkinson's disease	2.34e-06	1.33e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GSTM1—Parkinson's disease	2.33e-06	1.33e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—IL6—Parkinson's disease	2.28e-06	1.3e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—INS—Parkinson's disease	2.28e-06	1.3e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MAPK8—Parkinson's disease	2.28e-06	1.3e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—APOE—Parkinson's disease	2.26e-06	1.29e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—IL6—Parkinson's disease	2.25e-06	1.28e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GPX1—Parkinson's disease	2.23e-06	1.27e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—COMT—Parkinson's disease	2.22e-06	1.26e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GSTP1—Parkinson's disease	2.21e-06	1.26e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—MAOA—Parkinson's disease	2.2e-06	1.26e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—HMOX1—Parkinson's disease	2.18e-06	1.24e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MAPK8—Parkinson's disease	2.16e-06	1.23e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL6—Parkinson's disease	2.13e-06	1.21e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CASP3—Parkinson's disease	2.11e-06	1.2e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—COMT—Parkinson's disease	2.09e-06	1.19e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GSTP1—Parkinson's disease	2.08e-06	1.19e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—IL6—Parkinson's disease	2.08e-06	1.18e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—MAOA—Parkinson's disease	2.08e-06	1.18e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—COMT—Parkinson's disease	2.07e-06	1.18e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CASP3—Parkinson's disease	2.07e-06	1.18e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GSTP1—Parkinson's disease	2.06e-06	1.18e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—MTHFR—Parkinson's disease	2.06e-06	1.17e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—MAOA—Parkinson's disease	2.06e-06	1.17e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—HMOX1—Parkinson's disease	2.05e-06	1.17e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—HMOX1—Parkinson's disease	2.04e-06	1.16e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GSTM1—Parkinson's disease	2.03e-06	1.16e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—IL6—Parkinson's disease	2.02e-06	1.15e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ABCB1—Parkinson's disease	1.97e-06	1.12e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—IL6—Parkinson's disease	1.97e-06	1.12e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CASP3—Parkinson's disease	1.96e-06	1.12e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ABCB1—Parkinson's disease	1.95e-06	1.11e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GPX1—Parkinson's disease	1.94e-06	1.11e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MAPK8—Parkinson's disease	1.94e-06	1.11e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—INS—Parkinson's disease	1.93e-06	1.1e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IL6—Parkinson's disease	1.93e-06	1.1e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL6—Parkinson's disease	1.92e-06	1.09e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—APOE—Parkinson's disease	1.92e-06	1.09e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GSTM1—Parkinson's disease	1.91e-06	1.09e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MAPK8—Parkinson's disease	1.9e-06	1.08e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GSTM1—Parkinson's disease	1.9e-06	1.08e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL6—Parkinson's disease	1.88e-06	1.07e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL6—Parkinson's disease	1.87e-06	1.06e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GPX1—Parkinson's disease	1.83e-06	1.04e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GPX1—Parkinson's disease	1.82e-06	1.03e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP2D6—Parkinson's disease	1.8e-06	1.03e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MAPK8—Parkinson's disease	1.8e-06	1.03e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—MTHFR—Parkinson's disease	1.79e-06	1.02e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL6—Parkinson's disease	1.78e-06	1.01e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—IL6—Parkinson's disease	1.77e-06	1.01e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CTGF—Parkinson's disease	1.77e-06	1.01e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CASP3—Parkinson's disease	1.7e-06	9.66e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—MTHFR—Parkinson's disease	1.69e-06	9.63e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—MTHFR—Parkinson's disease	1.68e-06	9.55e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—APOE—Parkinson's disease	1.67e-06	9.51e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP2E1—Parkinson's disease	1.65e-06	9.4e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—INS—Parkinson's disease	1.64e-06	9.33e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—NQO1—Parkinson's disease	1.63e-06	9.29e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL6—Parkinson's disease	1.61e-06	9.19e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—TH—Parkinson's disease	1.61e-06	9.16e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL6—Parkinson's disease	1.6e-06	9.1e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—APOE—Parkinson's disease	1.57e-06	8.96e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—APOE—Parkinson's disease	1.56e-06	8.89e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MAPK8—Parkinson's disease	1.56e-06	8.88e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYCS—Parkinson's disease	1.54e-06	8.79e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL6—Parkinson's disease	1.54e-06	8.77e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL6—Parkinson's disease	1.45e-06	8.28e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—INS—Parkinson's disease	1.43e-06	8.13e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—IL6—Parkinson's disease	1.42e-06	8.1e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL6—Parkinson's disease	1.38e-06	7.84e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—COMT—Parkinson's disease	1.37e-06	7.79e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GSTP1—Parkinson's disease	1.36e-06	7.75e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—MAOA—Parkinson's disease	1.36e-06	7.73e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—INS—Parkinson's disease	1.34e-06	7.66e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—HMOX1—Parkinson's disease	1.34e-06	7.65e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—INS—Parkinson's disease	1.33e-06	7.59e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ABCB1—Parkinson's disease	1.29e-06	7.34e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GSTM1—Parkinson's disease	1.25e-06	7.12e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL6—Parkinson's disease	1.24e-06	7.06e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL6—Parkinson's disease	1.21e-06	6.92e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GPX1—Parkinson's disease	1.2e-06	6.82e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL6—Parkinson's disease	1.15e-06	6.56e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—MTHFR—Parkinson's disease	1.11e-06	6.3e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—APOE—Parkinson's disease	1.03e-06	5.86e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL6—Parkinson's disease	9.96e-07	5.67e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—INS—Parkinson's disease	8.79e-07	5.01e-06	CbGpPWpGaD
